US3736786068 - Common Stock
GEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth...
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and...
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against...
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and...
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Labs (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, has entered into a definitive securities purchase agreement with a certain institutional investor. The agreement is for the purchase and sale of 1,700,000 shares of the company’s common stock (or common stock equivalents), offered at $5 per share […]
Company to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for Control, Treatment, and Prevention ATLANTA, GA,...
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ATLANTA, GA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and...
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Company to Discuss Recent Mpox Developments as Well as Milestones Related to theBARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine ...
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Strategic Appointment Enhances GeoVax’s Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs,...
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GOVX stock results show that Geovax Labs beat analyst estimates for earnings per share the second quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Geovax Labs (NASDAQ:GOVX) just reported results for the second quarter of 2024....